The time has come for harmonized international ART registration
Publikation: Bidrag til tidsskrift › Kommentar/debat › Forskning › fagfællebedømt
For more than two decades, the European IVF-Monitoring Consortium has collected data on IVF in Europe with the aim of monitoring the quality and safety of assisted reproductive technology (ART) treatments, to ensure the highest performance with the lowest risk for patients and their offspring. Likewise, the Society for Assisted Reproductive Technology in the USA and the Australia/New Zealand Assisted Reproduction Database collect, process and publish data in their regions. The better the legal framework for ART surveillance, the more complete and reliable are the datasets. Worldwide, the landscape of ART regulation is fragmented, and until there is a legal obligation to report ART data in all countries, with an appropriate quality control of the data collected, the reported outcomes should be interpreted with caution. Once uniform and harmonized data are achieved, consensus reports based on collective findings can begin to address key topics such as cycle segmentation and complications. Improved registration systems and datasets allowing optimized surveillance should be developed in collaboration with patient representatives to consider patients’ needs, especially aiming to provide higher transparency around ART services. Support from national and international reproductive medicine societies will also be essential to the future evolution of ART registries.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Reproductive BioMedicine Online |
| Vol/bind | 46 |
| Udgave nummer | 6 |
| Sider (fra-til) | 881-885 |
| Antal sider | 5 |
| ISSN | 1472-6483 |
| DOI |
|
| Status | Udgivet - 2023 |
Bibliografisk note
Funding Information:
ICFO is an industry-funded initiative supported by Gedeon Richter. Editorial assistance was funded by Gedeon Richter. The sponsor had no role in the preparation or review of the manuscript.
Funding Information:
A.P. has received personal fees and research support from Gedeon Richter, MSD, Ferring, Merck, Organon, IBSA and Cryos. C.B. has received personal fees and non-financial support from Abbott, Besins, Ferring, Gedeon Richter, Merck, MSD and Organon. A.C. has received speaker and advisory board fees and expenses payments from Gedeon Richter, Cooper, Theramex, Merck and Ferring. G.C. has received personal fees from Gedeon Richter and non-financial support from Gedeon Richter and in previous years from IBSA and Excemed. J.A.G.-V. has received grants and speaker fees from Gedeon Richter, MSD, Merck Serono, Ferring and Theramex. At the time of submission, J.A.G.-V. was Joint Chief Editor of Reproductive BioMedicine Online; journal policy recused the author from having any role in the peer review of this manuscript. P.S. has received grants and speaker fees from Gedeon Richter, Merck Serono, Ferring, Ipsen and Besins Healthcare. C.D.G. has received grants from Ferring, MSD and IBSA and participated in the global advisory board of Ferring and the Swiss national advisory board of MSD. C.W. has received speaker and advisory board fees from Gedeon Richter, Merck and Ferring, and research grants from Ferring.
Publisher Copyright:
© 2023
ID: 363399293